Alkermes Plc (ALKS NASDAQ) stock market data APIs
$33.6667
0.53(1.6%)
as of February 5, 2026
Try our APIs with
free plan!
Alkermes Plc Financial Data Overview
Price chart is built with
Anychart
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Prev. Close
33.6667
Open
34.1928
High
34.5324
Low
33.5922
52 wk Range
25.165-36.45
Market Cap
5 635 M
P/E Ratio
16.9801
Shares Outstanding
165 M
Revenue
1 521 M
EPS
0.6508
Beta
0.458
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Alkermes Plc (top by weight)
Ticker
100-day Price Change
Weight
POAGX.US
PRIMECAP ODYSSEY AGGRESSIVE GROWTH FUND PRIMECAP ODYSSEY AGGRESSIVE GROWTH FUND
7.94
(18.6%)
2.34
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Alkermes Plc data using free add-ons & libraries
Get Alkermes Plc Fundamental Data
Alkermes Plc Fundamental data includes:
- Net Revenue: 1 521 M
- EBITDA: 389 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-23
- EPS/Forecast: 0.38
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Alkermes Plc News
New
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates
Bristol-Myers Squibb Company BMY reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.26, which beat the Zacks Consensus Estimate of $1.15. In the year-ago quarter, BMY posted adjusted...
FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway
AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has accepted and granted priority review to their supplemental biologics license application (sBLA) seeking approval o...
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View
Novo Nordisk A/S NVO reported adjusted fourth-quarter 2025 earnings of $1 per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 90 cents. The company had reported adjusted ...
Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study
Sanofi SNY announced that a late-stage study, evaluating venglustat, an investigational oral glucosylceramide synthase inhibitor (GCSi), in patients aged 12 years and older with type 3 Gaucher disease...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
